Is a company that develops and commercializes novel treatments for B-cell diseases
The stock initiated a bull trend at the end of 2023 after a breakaway gap and has gained +90% during 2024 and gave 2 opportunities to buy on breakouts
Now is forming a 3rd base and may give another opportunity to enter, all this while relative to its sector
XLV is making new highs
According to IBD is not among the industry leaders, but it has a 96 Relative Strength Rating against the
SPX
The stock initiated a bull trend at the end of 2023 after a breakaway gap and has gained +90% during 2024 and gave 2 opportunities to buy on breakouts
Now is forming a 3rd base and may give another opportunity to enter, all this while relative to its sector
XLV is making new highsAccording to IBD is not among the industry leaders, but it has a 96 Relative Strength Rating against the
SPX
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.